Literature DB >> 12700470

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.

Marta Boffito, David J Back, Patrick G Hoggard, Annamaria Caci, Stefano Bonora, Riccardo Raiteri, Alessandro Sinicco, Helen E Reynolds, Saye Khoo, Giovanni Di Perri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12700470     DOI： 10.1097/00002030-200305020-00029

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Authors:  Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Authors:  Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

3.  Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.

Authors:  Luis F Lopez-Cortes; Rosa Ruiz-Valderas; Elena Sánchez-Rivas; Amparo Lluch; Alicia Gutierrez-Valencia; Almudena Torres-Cornejo; Omar J Benmarzouk-Hidalgo; Pompeyo Viciana
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

Review 4.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19.

Authors:  Mario Karolyi; Sara Omid; Erich Pawelka; Bernd Jilma; Thomas Stimpfl; Christian Schoergenhofer; Hermann Laferl; Tamara Seitz; Marianna Traugott; Christoph Wenisch; Alexander Zoufaly
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

6.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.